Pulse Biosciences, Inc.
52.97USD
+4.1800 (+8.57%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.3▼ | $-0.24 | 0 | 1 |
| Next quarter | $-0.3▼ | $-0.23 | 0 | 1 |
| Current year | $-1.11▼ | $-0.91 | 1 | 0 |
| Next year | $-1.16▼ | $-0.88 | 1 | 0 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.29 | $-0.28 | +0.00 (+1.5%) |
| 2026-03-31 | $-0.22 | $-0.24 | -0.02 (-9.7%) |
| 2025-12-31 | $-0.21 | $-0.18 | +0.03 (+14.3%) |
| 2025-09-30 | $-0.31 | $-0.29 | +0.02 (+6.5%) |
17 ratings from 7 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Freedom Capital Markets | Initiated | Buy | $73 | Sep 9, 2026 |
| Needham | Initiated | Buy | $58 | Aug 17, 2026 |
| Canaccord Genuity | Maintained | Buy | $32 $43 | Aug 10, 2026 |
| Canaccord Genuity | Initiated | Buy | $32 | Jun 4, 2026 |
| Oppenheimer | Initiated | Outperform | $22 | Jul 7, 2025 |
| Maxim Group | Downgraded from Buy | Hold | — | Sep 21, 2022 |
| HC Wainwright & Co. | Downgraded from Buy | Neutral | — | May 13, 2022 |
| Stephens & Co. | Maintained | Overweight | $14 $12 | Apr 1, 2022 |
| HC Wainwright & Co. | Maintained | Buy | $20 $8.5 | Apr 1, 2022 |
| HC Wainwright & Co. | Maintained | Buy | $43 $20 | Feb 10, 2022 |
| HC Wainwright & Co. | Maintained | Buy | $46 $43 | Nov 16, 2021 |
| Stephens & Co. | Initiated | Overweight | $28 | Jul 27, 2021 |
| Maxim Group | Initiated | Buy | $40 | Mar 11, 2021 |
| HC Wainwright & Co. | Maintained | Buy | $16 $40 | Jan 26, 2021 |
| HC Wainwright & Co. | Upgraded from Neutral | Buy | $6 $16 | May 12, 2020 |
| HC Wainwright & Co. | Downgraded from Buy | Neutral | $6 | Feb 14, 2020 |
| HC Wainwright & Co. | Initiated | Buy | — | Feb 25, 2019 |
25 filings from 7 insiders · 0 buy / 0 sell over 6m
Officers and directors of PLSE, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DUGGAN ROBERT WILLIAMDirector and Beneficial Owner of more than 10% of a Class of Security | Buy | 660.2k | $19.69 | $13.00M | May 11, 2026 |
| LAVIOLETTE PAUL AChief Executive Officer | Buy | 15.0k | $19.69 | $295k | May 11, 2026 |
| DANAHY KEVIN PATRICKOfficer | Exercise | 5.0k | $1.53 | $8k | Feb 18, 2026 |
| DANAHY KEVIN PATRICKOfficer | Sell | 5.0k | $23.64 | $118k | Feb 18, 2026 |
| DANAHY KEVIN PATRICKOfficer | Exercise | 60.0k | $1.53 | $92k | Feb 17, 2026 |
| DANAHY KEVIN PATRICKOfficer | Sell | 60.0k | $23.37 | $1.41M | Feb 17, 2026 |
| DANAHY KEVIN PATRICKOfficer | Exercise | 60.0k | $1.53 | $92k | Feb 11, 2026 |
| DANAHY KEVIN PATRICKOfficer | Sell | 60.0k | $21.45 | $1.40M | Feb 11, 2026 |
| DANAHY KEVIN PATRICKOfficer | Exercise | 4.6k | $1.53 | $7k | Oct 2, 2025 |
| DANAHY KEVIN PATRICKOfficer | Sell | 4.6k | $18.53 | $85k | Oct 2, 2025 |
| DANAHY KEVIN PATRICKOfficer | Exercise | 20.4k | $1.53 | $31k | Sep 19, 2025 |
| DANAHY KEVIN PATRICKOfficer | Sell | 20.4k | $18.48 | $377k | Sep 19, 2025 |
| UECKER DARRIN RChief Technology Officer | Exercise | 206.5k | $4.00 | $826k | Sep 17, 2025 |
| UECKER DARRIN RChief Technology Officer | Sell | 45.0k | $16.21 | $731k | Sep 17, 2025 |
| UECKER DARRIN RChief Technology Officer | Exercise | 75.0k | $4.00 | $300k | Sep 15, 2025 |
| UECKER DARRIN RChief Technology Officer | Sell | 75.0k | $14.32 | $1.12M | Sep 15, 2025 |
| DUGGAN ROBERT WILLIAMDirector and Beneficial Owner of more than 10% of a Class of Security | Buy | 192.6k | $14.66 | $3.44M | Sep 10, 2025 |
| UECKER DARRIN RChief Technology Officer | Sell | 30.0k | $15.98 | $486k | Jun 13, 2025 |
| ZANGANEH MAHKAMDirector | Exercise | 60.2k | $11.00 | $663k | Feb 3, 2025 |
| DUGGAN ROBERT WILLIAMDirector and Beneficial Owner of more than 10% of a Class of Security | Exercise | 5.31M | $11.00 | $58.37M | Dec 18, 2024 |
No analyst notes on PLSE yet.
Analyst Ratings
4 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 3 | 0 | 0 | 0 | Buy1.75 |
| 1 mo ago | 0 | 3 | 0 | 0 | 0 | Buy2.00 |
| 2 mo ago | 0 | 3 | 0 | 0 | 0 | Buy2.00 |